1. Home
  2. INCY vs NWS Comparison

INCY vs NWS Comparison

Compare INCY & NWS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$106.24

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Logo News Corporation Class B

NWS

News Corporation Class B

HOLD

Current Price

$30.67

Market Cap

16.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
INCY
NWS
Founded
1991
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Newspapers/Magazines
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
17.0B
16.2B
IPO Year
1993
N/A

Fundamental Metrics

Financial Performance
Metric
INCY
NWS
Price
$106.24
$30.67
Analyst Decision
Buy
Strong Buy
Analyst Count
21
6
Target Price
$96.79
$37.34
AVG Volume (30 Days)
2.2M
962.5K
Earning Date
02-09-2026
02-04-2026
Dividend Yield
N/A
0.65%
EPS Growth
3878.02
230.83
EPS
5.90
2.06
Revenue
$4,813,105,000.00
$8,500,000,000.00
Revenue This Year
$19.59
$5.13
Revenue Next Year
$10.80
$3.30
P/E Ratio
$17.52
$13.27
Revenue Growth
18.09
2.20
52 Week Low
$53.56
$26.25
52 Week High
$112.29
$35.58

Technical Indicators

Market Signals
Indicator
INCY
NWS
Relative Strength Index (RSI) 57.76 66.49
Support Level $102.68 $29.29
Resistance Level $112.29 $30.54
Average True Range (ATR) 3.15 0.45
MACD 0.44 0.08
Stochastic Oscillator 58.73 91.06

Price Performance

Historical Comparison
INCY
NWS

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

About NWS News Corporation Class B

News Corporation is a diversified media conglomerate with large presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings platform in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.

Share on Social Networks: